Unlike anti-PD-1 therapy, which hinders the interaction between PD-1 and PD-L1, EGCG inhibits JAK/STAT signaling and reduces PD-L1 expression in tumor cells, leading to the reactivation of T cells. Here, PDCD1 is linked to neoplasm.